Committees and units

The EHA Board sets up committees and units to perform specific tasks and activities.

Chairs and Members

Chairs and members

Chair (2024–2027 term)Igor Aurer (education and scientific meetings co-lead) – University Hospital Centre Zagreb, University of Zagreb and KroHem, Croatia

Co-chair (2024–2027 term)Martin Dreyling (guidelines lead) – University Hospital Grosshadern, Ludwig Maximilian University and GLA, Germany

SWG Executive Board members (2024–2027 term)
Kim Linton (scientific secretary) –…

Chairs and Members

Chair (2020–2025 term)Prof Raúl Córdoba (Spain)

Vice-chairProf Valentín Goede (Germany)

SWG Executive Board
Sonja Zweegman (The Netherlands)—interest in multiple myeloma
Tamas Fulop (Canada)—interest in geriatrics and immunology
Giuseppe Rossi (Italy)—interest in indolent lymphomas
Dominique Bron (Belgium)—interest in lymphoma, CLL, and cognitive impairment
Sergio Storti (Italy)—interest in aggressive…

EHA-AHA Tutorial on Biology and Management of Myeloid Malignancies

In collaboration with the Armenian Hematology Association. Dates: October 20-21, 2017
Location: Yerevan, Armenia
Chairs: S Daghbashyan, JJ Kiladjian & P Fenaux
Language: English (with simultaneous translation to Russian)

Online registration is closed.

Immunoglobulin shortages in the spotlight: EMA, SUPPLY and the SoHO Regulation

EMA executive director Emer Cooke welcoming participants including EHA at the Shortages Workshop, March 1

 

Shortages of immunoglobulins and the need to increase and sustain plasma supplies have moved to the center of the EU policy and regulatory stage.

Integrated Diagnosis Strategies in Oncohematology for the Management of Cytopenias and Leukocytosis

111 hematologists from 31 countries met in Barcelona for a three-day scientific meeting on Integrated Diagnosis Strategies in Oncohematology for the Management of Cytopenias and Leukocytosis.

Treatment and survival of patients with chronic myeloid leukemia (CML) in Europe

Since the introduction of tyrosine kinase inhibitors into the treatment of CML survival times have greatly improved.